<trans-title xml:lang="en"/>_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

, 

中山大学肿瘤防治中心/华南肿瘤学国家重点实验室胃外科（广州 510060）;

Corresponding author：

, Email: zhouzhw@sysucc.org.cn

Keywords：

DOI：

10.7507/1007-9424.201701054

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 邱海波, 周志伟. . CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(2): 141-145. doi: 10.7507/1007-9424.201701054 Copy

1.	Stiller CA, Trama A, Serraino D,et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer, 2013, 49(3): 684-695.
2.	Miettinen M, Lasota J. Gastrointestinal stromal tumors. Gastroenterol Clin North Am, 2013, 42(2): 399-415.
3.	Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet, 2013, 382(9896): 973-983.
4.	Demetri GD, von Mehren M, Blanke CD,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7): 472-480.
5.	Demetri GD, van Oosterom AT, Garrett CR,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368(9544): 1329-1338.
6.	Demetri GD, Reichardt P, Kang YK,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 2013, 381(9863): 295-302.
7.	Fletcher CD, Berman JJ, Corless C,et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol, 2002, 33(5): 459-465.
8.	Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol, 2006, 23(2): 70-83.
9.	Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 2008, 39(10): 1411-1419.
10.	Gold JS, Gönen M, Gutiérrez A,et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol, 2009, 10(11): 1045-1052.
11.	Joensuu H, Vehtari A, Riihimäki J,et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol, 2012, 13(3): 265-274.
12.	Dematteo RP, Ballman KV, Antonescu CR,et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 2009, 373(9669): 1097-1104.
13.	Corless CL, Ballman KV, Antonescu CR,et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol, 2014, 32(15): 1563-1570.
14.	Joensuu H, Eriksson M, Sundby Hall K,et al. Onevs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA, 2012, 307(12): 1265-1272.
15.	Kindler HL, Campbell NP, Wroblewski K,et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago Phase Ⅱ Consortium trial. J Clin Oncol (ASCO Meeting Abstract), 2011, 29 (15 suppl; May 20 Supplement): abstr 10009.
16.	Ganjoo KN, Villalobos VM, Kamaya A,et al. A multicenter phase Ⅱ study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol, 2014, 25(1): 236-240.
17.	Dewaele B, Wasag B, Cools J,et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res, 2008, 14(18): 5749-5758.
18.	Trent JC WK, von Mehren M,et al. A phase Ⅱ study of dasatinib for patients with imatinib-resistant gastrointestinal stromaltumor (GIST) [abstract]. J Clin Oncol, 2011, 29(15_Suppl): Abstract 10006.
19.	Choi H, Charnsangavej C, Faria SC,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol, 2007, 25(13): 1753-1759.
20.	邱海波, 张鹏, 冯兴宇, 等. 中国四家医疗中心胃肠间质瘤诊断与治疗的 18 年变迁. 中华胃肠外科杂志, 2016, 19(11): 1265-1270.
21.	Hirota S, Isozaki K, Moriyama Y,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350): 577-580.
22.	Heinrich MC, Corless CL, Duensing A,et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299(5607): 708-710.
23.	Hirota S, Ohashi A, Nishida T,et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology, 2003, 125(3): 660-667.
24.	Janeway KA, Kim SY, Lodish M,et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA, 2011, 108(1): 314-318.
25.	Killian JK, Kim SY, Miettinen M,et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov, 2013, 3(6): 648-657.
26.	Boikos SA, Pappo AS, Killian JK,et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: A report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol, 2016, 2(7): 922-928.
27.	Güller U, Tarantino I, Cerny T,et al. Population-based SEER trend analysis of overall and cancer-specific survival in 5 138 patients with gastrointestinal stromal tumor. BMC Cancer, 2015, 15: 557.
28.	Guller U, Tarantino I, Cerny T,et al. Revisiting a dogma: similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis. Gastric Cancer, 2017, 20(1): 49-60.
29.	冯兴宇, 黎人杰, 张鹏, 等. 基于中国多中心数据的胃来源胃肠间质瘤外科治疗现状分析. 中华胃肠外科杂志, 2016, 19(11): 1258-1264.

1. Stiller CA, Trama A, Serraino D,et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer, 2013, 49(3): 684-695.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors. Gastroenterol Clin North Am, 2013, 42(2): 399-415.
3. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet, 2013, 382(9896): 973-983.
4. Demetri GD, von Mehren M, Blanke CD,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7): 472-480.
5. Demetri GD, van Oosterom AT, Garrett CR,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368(9544): 1329-1338.
6. Demetri GD, Reichardt P, Kang YK,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 2013, 381(9863): 295-302.
7. Fletcher CD, Berman JJ, Corless C,et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol, 2002, 33(5): 459-465.
8. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol, 2006, 23(2): 70-83.
9. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 2008, 39(10): 1411-1419.
10. Gold JS, Gönen M, Gutiérrez A,et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol, 2009, 10(11): 1045-1052.
11. Joensuu H, Vehtari A, Riihimäki J,et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol, 2012, 13(3): 265-274.
12. Dematteo RP, Ballman KV, Antonescu CR,et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 2009, 373(9669): 1097-1104.
13. Corless CL, Ballman KV, Antonescu CR,et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol, 2014, 32(15): 1563-1570.
14. Joensuu H, Eriksson M, Sundby Hall K,et al. Onevs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA, 2012, 307(12): 1265-1272.
15. Kindler HL, Campbell NP, Wroblewski K,et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago Phase Ⅱ Consortium trial. J Clin Oncol (ASCO Meeting Abstract), 2011, 29 (15 suppl; May 20 Supplement): abstr 10009.
16. Ganjoo KN, Villalobos VM, Kamaya A,et al. A multicenter phase Ⅱ study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol, 2014, 25(1): 236-240.
17. Dewaele B, Wasag B, Cools J,et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res, 2008, 14(18): 5749-5758.
18. Trent JC WK, von Mehren M,et al. A phase Ⅱ study of dasatinib for patients with imatinib-resistant gastrointestinal stromaltumor (GIST) [abstract]. J Clin Oncol, 2011, 29(15_Suppl): Abstract 10006.
19. Choi H, Charnsangavej C, Faria SC,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol, 2007, 25(13): 1753-1759.
20. 邱海波, 张鹏, 冯兴宇, 等. 中国四家医疗中心胃肠间质瘤诊断与治疗的 18 年变迁. 中华胃肠外科杂志, 2016, 19(11): 1265-1270.
21. Hirota S, Isozaki K, Moriyama Y,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350): 577-580.
22. Heinrich MC, Corless CL, Duensing A,et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299(5607): 708-710.
23. Hirota S, Ohashi A, Nishida T,et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology, 2003, 125(3): 660-667.
24. Janeway KA, Kim SY, Lodish M,et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA, 2011, 108(1): 314-318.
25. Killian JK, Kim SY, Miettinen M,et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov, 2013, 3(6): 648-657.
26. Boikos SA, Pappo AS, Killian JK,et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: A report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol, 2016, 2(7): 922-928.
27. Güller U, Tarantino I, Cerny T,et al. Population-based SEER trend analysis of overall and cancer-specific survival in 5 138 patients with gastrointestinal stromal tumor. BMC Cancer, 2015, 15: 557.
28. Guller U, Tarantino I, Cerny T,et al. Revisiting a dogma: similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis. Gastric Cancer, 2017, 20(1): 49-60.
29. 冯兴宇, 黎人杰, 张鹏, 等. 基于中国多中心数据的胃来源胃肠间质瘤外科治疗现状分析. 中华胃肠外科杂志, 2016, 19(11): 1258-1264.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content